Skip to content

Pre-workout Supplementation and Basketball

The Effect of a Pre-workout Supplement on Basketball-specific Performance and Biochemical Profile of Well-trained Athletes

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06059911
Enrollment
36
Registered
2023-09-29
Start date
2022-06-15
Completion date
2024-06-15
Last updated
2023-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sport Performance

Brief summary

Pre-workout supplements (PWS) consumption in recreationally or physically trained males lead to many performance-enhancing benefits, including improvements in mean power output during single and repeated sprints, agility, reaction times, lower body muscular endurance and reduced fatigue. PWS ingestion also improves anaerobic performance and prolongs time to exhaustion during high-intensity intermittent exercise. However, PWSs' effectiveness is not constant, as they do not alter anaerobic power, jumping performance or blood lactate concentrations after a training session, at least in recreationally trained males and strength-power athletes. Moreover, the effects of long-term PWS supplementation, where some nutritional agents were combined (e.g., β-alanine, creatine, citrulline malate, etc.) to assess endurance-trained runners or elite cyclists' performance, are mixed and less clear. Even though the popularity of PWS use has increased among trained/professional athletes, most of the data in this area are derived from recreationally and not from well-trained athletes of a competitive level (especially in team sports). Therefore, the present study aimed to examine the acute and chronic effects of a PWS, containing 200 mg caffeine, 3.3 g creatine monohydrate, 3.2 g βalanine, 6 g citrulline malate and 5 g BCAA per dose, on shooting, jumping, sprinting, agility, aerobic and anaerobic performance in well-trained basketball players.

Detailed description

According to a randomized, double-blind, placebo-controlled, research design, 36 well-trained male basketball players will be recruited. During their first visit, they will complete a health history and exercise questionnaire and will sign a written informed consent. Participants' dietary profile will be evaluated using 3- day diet recalls and they will be instructed to follow the same dietary scheme for 3 days prior to the subsequent evaluations. During the second visit, participants will be familiarized with the performance evaluations (shooting, jumping, sprinting, agility, running-based anaerobic sprint test and Yo-Yo intermittent recovery level 1 test). (Acute phase) One week later, Moreover, they will randomly be assigned in two groups (PWS and placebo) by a research member not involved in data collection. After that participants will visit the basketball court in the morning and a blood sample will be collected after overnight fasting. Afterward, the participants in each group will perform the evaluations without PWS or PL. The evaluations will be performed according to National Strength and Conditioning Association standards. Body composition, resting heart rate, blood pressure, basketball-specific shooting exercise, counter-movement jump, 20-m sprint, agility T-Test, running-based anaerobic sprint test and Yo-Yo intermittent recovery level 1 test. One week later, all participants will visit the same basketball court at the same hour and will consume the PWS or placebo supplement and 30 minutes later their physiological characteristics and performance will be evaluated in the same sequence. (Chronic phase) Following the evaluations of the acute phase, participants will continue the consumption of the PWS or placebo, according to their allocation group, daily for a period of 4 weeks. At the end of the supplementation period, participants will visit the basketball court and a second blood sample will be collected after overnight fasting (the first blood sample, collected before the acute phase evaluations, will serve as baseline). Then, participants' performance will be evaluated in the same sequence as the previous visit.

Interventions

DIETARY_SUPPLEMENTMulti-ingredient dietary supplement (caffeine, creatine monohydrate, β-alanine, citrulline malate, BCAA)

Administration of a multi-ingredient dietary supplement consisting of 200 mg caffeine, 3.3 g creatine monohydrate, 3.2 g β-alanine, 6 g citrulline malate and 5 g branched chain amino acids

DIETARY_SUPPLEMENTPlacebo dietary supplement (97% maltodextrin)

Administration of an isoenergetic placebo comparator dietary supplement consisting of 97% maltodextrin

Sponsors

Athanasios Z. Jamurtas
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
MALE
Age
18 Years to 41 Years
Healthy volunteers
Yes

Inclusion criteria

1. Male participants, 18-41 years old 2. Absence of drugs, abuse or medications, which are known to affect the Shooting, sprinting, jumping, agility, anaerobic and endurance performance 3. Consent to follow a regular dietary plan for basketball players

Exclusion criteria

1. Restraining orthopedic/neuromuscular problems 2. Caffeine hypersensitivity 3. Consumption of more than three servings of coffee per day 4. Use of any supplement or steroids prior to the study 5. Use of creatine, β-alanine, citrulline malate or BCAA-protein supplementation at least six months before the initiation of the study

Design outcomes

Primary

MeasureTime frameDescription
Serum glutamate-pyruvate transaminase activitybaseline and up to 4 weeksSerum glutamate-pyruvate transaminase will be measured on a clinical chemistry analyzer
Rate of basketball-specific shooting performancebaseline and up to 4 weeksBasketball-specific shooting performance will be evaluated with a test consisting of 30 free shoots, 30 middle-distance shoots and 30 long-distance shoots
Blood lactate concentartionbaseline and up to 4 weeksBlood lactate concentration will be measured using a portable blood lactate analyzer
Creatine kinase concentrationbaseline and up to 4 weeksCreatine kinase activity will be measured on a clinical chemistry analyzer
Lactate dehydrogenase concentrationbaseline and up to 4 weeksLactate dehydrogenase will be measured on a clinical chemistry analyzer
Serum glutamic-oxaloacetic transaminase activitybaseline and up to 4 weeksSerum glutamic-oxaloacetic transaminase will be measured on a clinical chemistry analyzer
Gamma-glutamyltransferase concentrationbaseline and up to 4 weeksGamma-glutamyltransferase will be measured on a clinical chemistry analyzer
Urea concentrationbaseline and up to 4 weeksUrea will be measured on a clinical chemistry analyzer
Creatinine concentrationbaseline and up to 4 weeksCreatinine will be measured on a clinical chemistry analyzer
Alkaline phosphatase concentrationbaseline and up to 4 weeksAlkaline phosphatase will be measured on a clinical chemistry analyzer
Countermovement jump heightbaseline and up to 4 weeksJumping performance will be evaluated using a contact platform
20 meters sprint running timebaseline and up to 4 weeksSprint performance will be evaluated using photocell gates
Rate of agility T-test performancebaseline and up to 4 weeksAgility T-test will be evaluated using photocell gates
Rate of running-based anaerobic sprint test performancebaseline and up to 4 weeksRunning-based anaerobic sprint test performance will be evaluated using photocell gates
Rate of Yo-Yo intermittent recovery test level 1 test performancebaseline and up to 4 weeksYo-Yo intermittent recovery test level 1 test performance will be evaluated using a field-based test

Secondary

MeasureTime frameDescription
Body heightbaseline and up to 4 weeksBody height will be measured using a stadiometer
Body fat massbaseline and up to 4 weeksBody fat mass will be measured using a calibrated digital scale via bioelectrical impedance analysis
Systolic and diastolic blood pressurebaseline and up to 4 weeksSystolic and diastolic blood pressure will be measured using a blood pressure monitor
Heart ratebaseline and up to 4 weeksHeart rate will be measured using a heart rate monitor
Body massbaseline and up to 4 weeksBody mass will be measured using a calibrated digital scale

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026